文献速递乳腺癌头颈与中枢神经肿瘤

脑放疗联合吡咯替尼与卡培他滨治疗ERBB2阳性晚期乳腺癌脑转移患者:一项非随机2期试验

Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项单臂、单中心、2期非随机临床试验评估了放疗联合吡咯替尼和卡培他滨在ERBB2阳性乳腺癌脑转移患者中的活性和安全性。共40例女性患者入组,1年中枢神经系统无进展生存率为74.9%,中枢神经系统客观缓解率为85%,最常见3或4级治疗相关不良事件为腹泻(7.5%)。作者认为该联合方案与较长的颅内生存获益相关且安全性可接受,值得进一步验证。

要点

  • 1年中枢神经系统无进展生存率为74.9%,中位中枢神经系统无进展生存期为18.0个月。
  • 中枢神经系统客观缓解率为85%(34/40),中位总生存期未达到。
  • 最常见的3或4级治疗相关不良事件为腹泻(7.5%),无症状放射性坏死见于4/67个病灶(6.0%)。

核心结论

  • 放疗联合吡咯替尼和卡培他滨在ERBB2阳性晚期乳腺癌脑转移患者中与较长的颅内生存获益相关,且安全性可接受。
  • 作者认为该联合方案值得进一步验证。

研究设计与样本

  • 单臂、单中心、2期非随机临床试验,含安全性导入期。
  • 2020年1月至2022年8月入组ERBB2阳性乳腺癌脑转移患者,数据截止日期为2023年2月1日。
  • 共40例女性患者接受治疗,包括安全性导入期3例;中位年龄50.5岁(IQR,46-59岁)。
  • 患者接受分次立体定向放疗或全脑放疗。
  • 吡咯替尼400 mg每日一次,卡培他滨1000 mg/m2每日两次,每21天周期第1-14天给药,从放疗第一天开始至放疗完成后第七天,并持续至疾病进展或不可接受的毒性。

主要发现

  • 中位随访17.3个月(IQR,10.3-26.9),1年中枢神经系统无进展生存率为74.9%(95% CI,61.9%-90.7%),中位中枢神经系统无进展生存期为18.0个月(95% CI,15.5至未达到)。
  • 1年无进展生存率为66.9%(95% CI,53.1%-84.2%),中位无进展生存期为17.6个月(95% CI,12.8-34.1)。
  • 中枢神经系统客观缓解率为85%(34/40),中位总生存期未达到。
  • 最常见的3或4级治疗相关不良事件为腹泻(7.5%)。
  • 分次立体定向放疗治疗的67个病灶中,无症状放射性坏死4个(6.0%);多数患者在不同时间点通过简易精神状态检查评估维持了神经认知功能。

关键数值与推荐

  • 主要终点为1年中枢神经系统无进展生存率,结果为74.9%(95% CI,61.9%-90.7%)。
  • 次要终点包括中枢神经系统客观缓解率85%(34/40)、中位无进展生存期17.6个月(95% CI,12.8-34.1)、中位总生存期未达到、安全性及神经认知功能变化。
  • 吡咯替尼剂量为400 mg每日一次,卡培他滨剂量为1000 mg/m2每日两次,每21天周期第1-14天给药。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为放疗联合吡咯替尼和卡培他滨与较长的颅内生存获益相关且安全性可接受,值得进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The potential benefit of combining intracranial effective systemic therapy with radiotherapy for patients with breast cancer with brain metastases remains unclear. OBJECTIVE: To assess the activity and safety of combining radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive breast cancer and brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm, single-center, phase 2 nonrandomized clinical trial with a safety run-in phase. Between January 2020 and August 2022, patients with ERBB2-positive breast cancer and brain metastases were enrolled. The data cutoff date was February 1, 2023. INTERVENTIONS: Patients received either fractionated stereotactic radiotherapy or whole-brain radiotherapy. Treatment with pyrotinib (400 mg, once daily) and capecitabine (1000 mg/m2, twice daily, on days 1-14 of each 21-day cycle) was initiated from the first day of radiotherapy to the seventh day after the completion of radiotherapy and continued until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was 1-year central nervous system (CNS) progression-free survival (PFS) rate. Secondary end points included CNS objective response rate (ORR), PFS, overall survival (OS), safety, and changes in neurocognitive function. RESULTS: A total of 40 female patients (median age, 50.5 years [IQR, 46-59 years]) were enrolled and received treatment, including 3 patients in safety run-in phase. With a median follow-up of 17.3 months (IQR, 10.3-26.9), the 1-year CNS PFS rate was 74.9% (95% CI, 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI, 15.5 to not reached). The 1-year PFS rate was 66.9% (95% CI, 53.1%-84.2%), and the median PFS was 17.6 months (95% CI, 12.8-34.1). The CNS objective response rate was 85% (34 of 40). Median overall survival was not reached. The most common grade 3 or 4 treatment-related adverse event was diarrhea (7.5%). Asymptomatic radiation necrosis was identified in 4 of 67 lesions (6.0%) treated with fractionated stereotactic radiotherapy. Most patients maintained neurocognitive function, as evaluated by the Mini-Mental State Examination at different points. CONCLUSIONS AND RELEVANCE: The results of this trial suggest that radiotherapy combined with pyrotinib and capecitabine is associated with long intracranial survival benefit in patients with ERBB2-positive advanced breast cancer and brain metastases with an acceptable safety profile. This combination deserves further validation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04582968.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yang Z, Meng J, Mei X, et al. Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2024. PMID: 38175627. doi:10.1001/jamaoncol.2023.5791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。